Oncogenes and tumor suppressor genes in prostate cancer: A review

Urologic Oncology

Volumn 3, Issue 2, 1997, Pages 41-46

  Wang, Y Z ^a   Wong, Y C ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Oncogenes; Prostate cancer; Tumor suppressor genes

Indexed keywords

ANDROGEN; ANTIBODY; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; MESSENGER RNA; MYC PROTEIN; PROTEIN; PROTEIN P21; PROTEIN P53; UVOMORULIN;

ARTICLE; CANCER GROWTH; CARCINOGENESIS; CHROMOSOME; GENE ACTIVATION; GENE EXPRESSION; GENE MUTATION; HUMAN; NONHUMAN; ONCOGENE; ONCOGENE C FOS; ONCOGENE C JUN; ONCOGENE C MYC; ONCOGENE NEU; ONCOGENE RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROTO ONCOGENE; RNA TRANSCRIPTION; SINGLE STRAND CONFORMATION POLYMORPHISM; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

EID: 0030782230     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(97)00021-5     Document Type: Article

References (81)

1. Peehl DM. Oncogenes in prostate cancer. An update. Cancer 1993;71(3 suppl):1159-64.
2. Huncharek M, Muscat J. Genetic characteristics of prostate cancer. Cancer Epidemiol Biomarkers Prev 1995;4(6):681-7.
3. Moul JW, Friedrichs PA, Lance RS, Theune SM, Chang EH. Infrequent RAS oncogene mutations in human prostate cancer. Prostate 1992;20(4):327-38.
4. Viola MV, Fromowitz F, Oravez S, et al. Expression of ras oncogene p21 in prostate cancer. N Engl J Med 1986;314(3): 133-7.
5. Varma VA, Austin GE, O'Connell AC. Antibodies to ras oncogene p21 proteins lack immunohistochemical specificity for neoplastic epithelium in human prostate tissue. Arch Pathol Lab Med 1989;113(1):16-9.
6. Bushman EC, Nayak RN, Bushman W. Immunohistochemical staining of ras p21: Staining in benign and malignant prostate tissue. J Urol 1995;153(1):233-7.
7. Fan K. Heterogeneous subpopulation of human prostatic adenocarcinoma cell: Potential usefulness of p21 protein as a predictor for bone metastasis. J Urol 1988;139(2):318-22.
8. Agnantis NJ, Constantinidou AE, Papaevagelou M, Apostolikas N. Comparative immunohistochemical study of ras-p21 oncoprotein in adenomatous hyperplasia and adenocarcinoma of the prostate gland. Anticancer Res 1994;14(5B):2135-40.
9. Niman HL, Tompson AM, Yu A, et al. Antipeptide antibodies detect oncogene-related protein in urine. Proc Natl Acad Sci USA 1985;82(23):7924-8.
10. Pergolizzi RG, Kreis W, Rottach C, Susin M, Broome JD. Mutational status of codons 12 and 13 of the N-and K-ras genes in tissue and cell lines derived from primary and metastatic prostatic carcinomas. Cancer Invest 1993;11(1):25-32.
11. Yu M, Leav BA, Leav I, Merk FB, Wolfe HJ, Ho SM. Early alterations in ras protooncogene mRNA expression in testosterone and estradiol-17 beta induced prostatic dysplasia of noble rats. Lab Invest 1993;68(1):33-44.
12. Rijnders AW, van-der-Korput JA, van-Steenbrugge GJ, Romijn JC, Trapman J. Expression of cellular oncogenes in human prostatic carcinoma cell lines. Biochem Biophys Res Commun 1985;132(2):548-54.
13. Cooke DB, Quarmby VE, Petrusz P, et al. Expression of ras proto-oncogenes in the Dunning R3327 rat prostatic adenocarcinoma system. Prostate 1988;13(4):273-87.
14. Carter BS, Epstein JI, Isaacs WB. ras gene mutations in human prostate cancer. Cancer Res 1990;50(21):6830-2.
15. Isaacs WB, Bova GS, Morton RA, Bussemakers MJ, Brooks JD, Ewing CM. Genetic alterations in prostate cancer. Cold Spring Harb Symp Quant Biol 1994;59:653-9.
16. Moyret-Lalle C, Marcais C, Jacquemier J, et al. ras, p53 and HPV status in benign and malignant prostate tumors. Int J Cancer 1995;64(2):124-9.
17. Konishi N, Enomoto T, Buzard G, Ohshima M, Ward JM, Rice JM. K-ras activation and ras p21 expression in latent prostate carcinomas in Japanese men. Cancer 1992;69(9):2293-9.
18. Anwar K, Nakakuki K, Shiraishi T, Naiki H, Yatani R, Inuzukam M. Presence of ras oncogene mutations and human papilloma-virus DNA in human prostate carcinoma. Cancer Res 1992; 52(21):5991-6.
19. Suzuki H, Aida S, Akimoto S, Igarashi T, Yatani R, Shimazaki J. State of adenomatous polyposis coli gene and ras oncogenes in Japanese prostate cancer. Jpn J Cancer Res 1994;85(8):847-52.
20. Strohmeyer TG, Slamon DJ. Proto-oncogenes and tumor suppressor genes in human urological maliganices. J Urol 1994; 151(6):1479-97.
21. Cohen RJ, Cooper K, Haffejee Z, Robinson E, Becker PJ. Immunohistochemical detection of oncogene proteins and neuroendocrine differentiation in different stages of prostate cancer. Pathology 1995;27(3):229-32.
22. Fleming WH, Hamel A, MacDonald R, et al. Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia. Cancer Res 1986;46(3):1535-8.
23. Buttyan R, Sawczuk IS, Benson MC, Siegal JD, Olsson CA. Enhanced expression of the c-myc proto-oncogene in high-grade human prostate cancers. Prostate 1987;11(4):327-37.
24. Eaton CL, Davies P, Phillips ME. Growth factor involvement and oncogene expression in prostatic tumors. J Steroid Biochem 1988;30(1-6):341-5.
25. Funa K, Nordgren H, Nilsson S. In situ expression of mRNA of proto-oncogenes in benign prostatic hyperplasia and in prostatic carcinoma. Scand J Urol Nephorol 1991;25(2):95-100.
26. Nag A, Smith RG. Amplification, rearrangement and elevated expression of c-myc in the human prostatic carcinoma cell line LNCaP. Prostate 1989;15(2):115-22.
27. Degeorges A, Hoffschir F, Cussenot O, et al. Recurrent cytogenetic alterations of prostate carcinoma and amplification of c-myc or epidermal growth factor receptor in subclones of immortalized PNT1 human prostate epithelial cell line. Int J Cancer 1995;62(6):724-31.
28. Thompson TC, Southgate J, Kitchener G, Land H. Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 1989;56(6):917-30.
29. Thompson TC. Growth factors and oncogenes in prostate cancer. Cancer Cells 1990;2(11):345-54.
30. Thompson TC, Kadmon D, Timme TL, et al. Experimental oncogene induced prostate cancer. Cancer Surv 1991;11:55-71.
31. Phillips ME, Ferro MA, Smith PJB, Davies P. Intranuclear androgen receptor deployment and proto-oncogene expression in human diseased prostate. Urol Int 1987;42(2):115-9.
32. Fudge K, Wang CY, Stearns ME. Immunohistochemical analysis of PDGF A/B chain and PDGF alpha and beta receptor expression in BPH and Gleason graded human prostate adenocarcinoma. Proc Am Assoc Cancer Res 1993;34:193(1151).
33. Lucibello FC, Muller R. Transcription factor encoding oncogenes. Rev Physiol Biochem Pharmacol 1992;119:225-57.
34. Merz VW, Arnold AM, Studer UE. Differential expression of transforming growth factor-beta 1 and beta 3 as well as c-fos mRNA in normal human prostate, benign prostatic hyperplasia and prostatic cancer. World J Urol 1994;12(2):96-8.
35. Wong YC, Wang YZ. Influence of mesenchyme on the expression of c-fos and c-jun proto-oncogenes in rat prostatic Dunning tumor (DT). Prostate 1996;6(suppl):99.
36. Zhau HE, Wan DS, Zhou J, Miller GJ, von-Eschenbach AC. Expression of c-erb B-2/neu proto-oncogene in human prostatic cancer tissues and cell lines. Mol Carcinog 1992;5(4): 320-7.
37. Kuhn EJ, Kurnot RA, Sesterhenn IA, Chang EH, Moul JW. Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. J Urol 1993;150(5 Pt 1):1427-33.
38. Sikes RA, Chung LW. Acquisition of a tumorigenic phenotype by a rat ventral prostate epithelial cell line expressing a transfected activated neu oncogene. Cancer Res 1992;52(11): 3174-81.
39. Zhau HY, Zhou J, Symmans WF, et al. Transfected neu oncogene induces human prostate cancer metastasis. Prostate 1996;28(2):73-83.
40. Sadasivan R, Morgan R, Jennings S, et al. Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer. J Urol 1993;150(1):126-31.
41. Segal NH, Cohen RJ, Haffejee Z, Savage N. BCL-2 protooncogene expression in prostate cancer and its relationship to the prostatic neuroendocrine cell. Arch Pathol Lab Med 1994; 118(6):616-8.
42. Matsushima H, Hosaka Y, Suzuki M, Mizutani T, Ishizuka H, Kawabe K. bcl-2 expression on prostate cancer and its relationship to cell cycle and prognosis. Int J Urol 1996;3(2):113-7.
43. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995;55(19):4438-45.
44. McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52(24):6940-4.
45. Marin MC, Fernandez A, Bick RJ, et al. Apoptosis suppression by bcl-2 is correlated with the regulation of nuclear and cytosolic Ca2+. Oncogene 1996;12(11):2259-66.
46. Bubendorf L, Sauter G, Moch H, et al. Prognostic significance of Bcl-2 in clinically localized prostate cancer. Am J Pathol 1996;148(5):1557-65.
47. Marx J. Learning how to suppress cancer. Science 1993; 261(10):1385-7.
48. Kallioniemi A, Kallioniemi OP, Sudar D, et al. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 1992;258(5083):818-21.
49. Bookstein R, Shew JY, Chen PL, Scully P, Lee WH. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated Rb gene. Science 1990;247(4943):712-5.
50. Kubota Y, Fujinami K, Uemura H, et al. Retinoblastoma gene mutations in primary human prostate cancer. Prostate 1995; 27(6):314-20.
51. Isaacs WB. Molecular genetics of prostate cancer. Cancer Surv 1995;25:357-79.
52. Heidenberg HB, Sesterhenn IA, Gaddipati JP, et al. Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J Urol 1995;154(2 pt 1): 414-21.
53. Isaacs WB, Carter BS, Ewing CM. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 1991;51(17):4716-20.
54. Rubin SJ, Hallahan DE, Ashman CR, et al. Two prostate carcinoma cell lines demonstrate abnormalities in tumor suppressor genes. J Surg Oncol 1991;46(1):31-6.
55. Mellon K, Thompson S, Charlton RG, et al. p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. J Urol 1992;147(2):496-9.
56. Van-Veldhuizen PJ, Sadasivan R, Garcia F, Austenfeld MS, Stephens RL. Mutant p53 expression in prostate carcinoma. Prostate 1993;22(1):23-30.
57. Moul JW, Bettencourt MC, Sesterhenn IA, et al. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery 1996;120(2):159-66, 166-7.
58. Stricker HJ, Jay JK, Linden MD, Tamboli P, Amin MB. Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53. Urology 1996; 47(3):366-9.
59. Dahiya R, Deng G, Chen KM, Chui RM, Haughney PC, Narayan P. P53 tumour-suppressor gene mutations are mainly localised on exon 7 in human primary and metastatic prostate cancer. Br J Cancer 1996;74(2):264-8.
60. Brooks JD, Bova GS, Ewing CM, et al. An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res 1996; 56(16):3814-22.
61. Kunimi K, Amano T, Uchibayashi T. Point mutation of the p53 gene is an infrequent event in untreated prostate cancer. Cancer Detect Prev 1996;20(3):218-22.
62. Srivastava S, Katayose D, Tong YA, et al. Recombinant adenovirus vector expressing wild-type p53 is a potent inhibitor of prostate cancer cell proliferation. Urology 1995;46(6):843-8.
63. Yang C, Cirielli C, Capogrossi MC, Passaniti A. Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res 1995;55(19):4210-3.
64. Rinker-Schaeffer CW, Hawkins AL, Ru N, et al. Differential suppression of mammary and prostate cancer metastasis by human chromosomes 17 and 11. Cancer Res 1994;54(23): 6249-56.
65. Fishman JR, Gumerlock PH, Meyers FJ, deVere-White RW. Quantitation of NM23 expression in human prostate tissues. J Urol 1994;152(1):202-7.
66. Bussemakers MJ, van-Moorselaar RJ, Giroldi LA, et al. Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res 1992;52(10):2916-22.
67. Umbas R, Schalken JA, Aalders TW, et al. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 1992;52(18):5104-9.
68. Umbas R, Isaacs WB, Bringuier PP, et al. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994;54(14):3929-33.
69. Cheng L, Nagabhushan M, Pretlow TP, Amini SB, Pretlow TG. Expression of E-cadherin in primary and metastatic prostate cancer. Am J Pathol 1996;148(5):1375-80.
70. Ewing CM, Ru N, Morton RA, et al. Chromosome 5 suppresses tumorigenicity of PC3 prostate cancer cells: Correlation with re-expression of alpha-catenin and restoration of E-cadherin function. Cancer Res 1995;55(21):4813-7.
71. Dong JT, Lamb PW, Rinker-Schaeffer CW, et al. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 1995;268(5212):884-6.
72. Dong JT, Suzuki H, Pin SS, et al. Down-regulation of KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res 1996;56(19):4387-90.
73. Marx J. New clue to prostate cancer spread. Science 1995; 268(5212):799-800.
74. Sanchez Y, Lovell M, Marin MC, et al. Tumor suppression and apoptosis of human prostate carcinoma mediated by a genetic locus within human chromosome 10pter-q11. Proc Natl Acad Sci USA 1996;93(6):2551-6.
75. Cooney KA, Wetzel JC, Consolino CM, Wojno KJ. Identification and characterization of proximal 6q deletions in prostate cancer. Cancer Res 1996a;56(18):4150-3.
76. Cher ML, Bova GS, Moore DH, et al. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res 1996;56(13):3091-102.
77. Cooney KA, Wetzel JC, Merajver SD, Macoska JA, Singleton TP, Wojno KJ. Distinct regions of allelic loss on 13q in prostate cancer. Cancer Res 1996;56(5):1142-5.
78. Vocke CD, Pozzatti RO, Bostwick DG, et al. Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. Cancer Res 1996; 56(10):2411-6.
79. Trybus TM, Burgess AC, Wojno KJ, Glover TW, Macoska JA. Distinct areas of allelic loss on chromosomal regions 10p and 10q in human prostate cancer. Cancer Res 1996;56(10):2263-7.
80. Ittmann M. Allelic loss on chromosome 10 in prostate adenocarcinoma. Cancer Res 1996;56(9):2143-7.
81. Williams BJ, Jones E, Zhu XL, et al. Evidence for a tumor suppressor gene distal to BRCA1 in prostate cancer. J Urol 1996;155(2):720-5.